Southern Illinois University
Latest From Southern Illinois University
While Lipocine Inc. is at the nail-biting stage of development for its oral testosterone Tlando (LPCN 1021) – awaiting a US FDA approval decision – urologists continue to study testosterone therapy to determine whether treatment of hypogonadal men is safe with appropriate monitoring.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.